UBS’s Aurinia Pharmaceuticals AUPH Stock Holding History

UBS’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$0	Buy	+40	New	+$142	﹤0.01%	10342

Other funds holding AUPH

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

CCMU

Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return

UBS's AUPH Position: Q3 2014 in Review

UBS opened a new position in Aurinia Pharmaceuticals (AUPH) in Q3 2014: 40 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #10342 among its holdings.

11 funds tracked by Wall St. Rank hold AUPH as of Q3 2014.

UBS held 40 shares of Aurinia Pharmaceuticals worth $0 as of Q3 2014.
Aurinia Pharmaceuticals was a new UBS position in Q3 2014.
Aurinia Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10342 holding.
11 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.